CORRECTED-Liquidia reports Q2 revenue of $8.8 mln, net loss widens

Overview

• Liquidia reports Q2 revenue of $8.8 mln following YUTREPIA launch

• Net loss for Q2 widens to $41.6 mln due to commercialization costs

• Co reports positive interim ASCENT trial data for YUTREPIA

Outlook

• Liquidia plans to expand market access for YUTREPIA in Q3 and Q4

• Company aims to scale YUTREPIA access and expand clinical programs

• Liquidia to present detailed clinical data at conferences in September and October

• Company targets occupancy of new manufacturing space in 2026

Result Drivers

• YUTREPIA LAUNCH - Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval, reflecting strong demand

• COMMERCIALIZATION COSTS - Increased expenses due to YUTREPIA launch and legal fees contributed to wider net loss

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Liquidia Corp is $32.00, about 33.8% above its August 11 closing price of $21.20

Press Release: ID:nGNXbb1x4H